Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 17/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22771445 | 1.00 | TGFBR1 (0.52) | TGFBR1GRIN2BGRIN1FGFR1CYP1A2 | |
| SCHEMBL30133030 | 0.86 | PDGFRB (0.48) | TGFBR1GRIN2BGRIN1FGFR1 | |
| SCHEMBL30117390 | 0.83 | TGFBR1 (0.51) | TGFBR1GRIN2BGRIN1CYP1A2CYP2C9 | |
| SCHEMBL15639521 | 0.83 | TGFBR1 (0.51) | TGFBR1GRIN2BGRIN1CYP1A2CYP2C9 | |
| SCHEMBL30133051 | 0.82 | RAF1 (0.47) | GRIN2BGRIN1FGFR1 | |
| SCHEMBL22771417 | 0.81 | GRIN2B (0.51) | GRIN2BGRIN1KCNH2 | |
| SCHEMBL22771356 | 0.81 | GRIN2B (0.51) | GRIN2BGRIN1KCNH2 | |
| SCHEMBL29901554 | 0.80 | GRIN2B (0.52) | GRIN2BGRIN1 | |
| SCHEMBL29525098 | 0.80 | DYRK1A (0.49) | TGFBR1GRIN2BGRIN1FGFR1 | |
| SCHEMBL17754852 | 0.80 | DYRK1A (0.49) | TGFBR1GRIN2BGRIN1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530210-B2 | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-20 | — | — | US | disclosed |
| US-20220324860-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-13 | — | — | US | disclosed |
| EP-3983075-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3982958-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3983073-A1 | SUBSTITUTED PYRAZOLO[4,3-B]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324860-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN3B, GRIN3A | TGFBR1 1233/4885GRIN2B 1/4885GRIN1 7/4885 |
| US-11530210-B2 | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | TGFBR1 1298/4885GRIN2B 1/4885GRIN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.